Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression

Carlos Moreno-Yruela, Daniel M. Fass, Chialin Cheng, Joachim Herz, Christian A. Olsen, Stephen J. Haggarty

Research output: Contribution to journalArticle

Abstract

Histone deacetylases (HDACs) are enzymes involved in the epigenetic control of gene expression. A handful of HDAC inhibitors have been approved for the treatment of cancer, and HDAC inhibition has also been proposed as a novel therapeutic strategy for neurodegenerative disorders. These disorders include progranulin (PGRN)-deficient forms of frontotemporal dementia caused by mutations in the GRN gene that lead to haploinsufficiency. Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect. These observations indicate that the kinetics of HDAC inhibitor binding can be tuned for optimal induction of human PGRN expression in neurons. Here, we further expand on these findings using human cortical-like, glutamatergic neurons. We provide evidence that two prototypical, potent hydroxamic acid HDAC inhibitors that induce PGRN (panobinostat and trichostatin A) exhibit an initial fast-binding step followed by a second, slower step, referred to as mechanism B of slow binding, rather than simpler fast-on/fast-off binding kinetics. In addition, we show that trapoxin A, a macrocyclic, epoxyketone-containing class I HDAC inhibitor, exhibits slow binding with high, picomolar potency and also induces PGRN expression in human neurons. Finally, we demonstrate induction of PGRN expression by fast-on/fast-off, highly potent, macrocyclic HDAC inhibitors with ethyl ketone or ethyl ester Zn2+ binding groups. Taken together, these data expand our understanding of HDAC1-3 inhibitor binding kinetics, and further delineate the specific combinations of structural and kinetic features of HDAC inhibitors that are optimal for upregulating PGRN expression in human neurons and thus may have translational relevance in neurodegenerative disease.

Original languageEnglish (US)
Pages (from-to)3769-3777
Number of pages9
JournalACS Chemical Neuroscience
Volume10
Issue number8
DOIs
StatePublished - Aug 21 2019

Fingerprint

Histone Deacetylases
Tuning
Kinetics
Neurons
Hydroxamic Acids
Neurodegenerative Diseases
trichostatin A
Neurodegenerative diseases
Haploinsufficiency
Frontotemporal Dementia
Ketones
Epigenomics
Gene expression
Esters
Genes
Gene Expression
Mutation

Keywords

  • Epigenetic
  • histone deacetylase
  • kinetic profiling
  • panobinostat
  • progranulin
  • slow-binding inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression. / Moreno-Yruela, Carlos; Fass, Daniel M.; Cheng, Chialin; Herz, Joachim; Olsen, Christian A.; Haggarty, Stephen J.

In: ACS Chemical Neuroscience, Vol. 10, No. 8, 21.08.2019, p. 3769-3777.

Research output: Contribution to journalArticle

Moreno-Yruela, Carlos ; Fass, Daniel M. ; Cheng, Chialin ; Herz, Joachim ; Olsen, Christian A. ; Haggarty, Stephen J. / Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression. In: ACS Chemical Neuroscience. 2019 ; Vol. 10, No. 8. pp. 3769-3777.
@article{be53b08303de42daa5863478cd2b8c5b,
title = "Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression",
abstract = "Histone deacetylases (HDACs) are enzymes involved in the epigenetic control of gene expression. A handful of HDAC inhibitors have been approved for the treatment of cancer, and HDAC inhibition has also been proposed as a novel therapeutic strategy for neurodegenerative disorders. These disorders include progranulin (PGRN)-deficient forms of frontotemporal dementia caused by mutations in the GRN gene that lead to haploinsufficiency. Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect. These observations indicate that the kinetics of HDAC inhibitor binding can be tuned for optimal induction of human PGRN expression in neurons. Here, we further expand on these findings using human cortical-like, glutamatergic neurons. We provide evidence that two prototypical, potent hydroxamic acid HDAC inhibitors that induce PGRN (panobinostat and trichostatin A) exhibit an initial fast-binding step followed by a second, slower step, referred to as mechanism B of slow binding, rather than simpler fast-on/fast-off binding kinetics. In addition, we show that trapoxin A, a macrocyclic, epoxyketone-containing class I HDAC inhibitor, exhibits slow binding with high, picomolar potency and also induces PGRN expression in human neurons. Finally, we demonstrate induction of PGRN expression by fast-on/fast-off, highly potent, macrocyclic HDAC inhibitors with ethyl ketone or ethyl ester Zn2+ binding groups. Taken together, these data expand our understanding of HDAC1-3 inhibitor binding kinetics, and further delineate the specific combinations of structural and kinetic features of HDAC inhibitors that are optimal for upregulating PGRN expression in human neurons and thus may have translational relevance in neurodegenerative disease.",
keywords = "Epigenetic, histone deacetylase, kinetic profiling, panobinostat, progranulin, slow-binding inhibitor",
author = "Carlos Moreno-Yruela and Fass, {Daniel M.} and Chialin Cheng and Joachim Herz and Olsen, {Christian A.} and Haggarty, {Stephen J.}",
year = "2019",
month = "8",
day = "21",
doi = "10.1021/acschemneuro.9b00281",
language = "English (US)",
volume = "10",
pages = "3769--3777",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "8",

}

TY - JOUR

T1 - Kinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression

AU - Moreno-Yruela, Carlos

AU - Fass, Daniel M.

AU - Cheng, Chialin

AU - Herz, Joachim

AU - Olsen, Christian A.

AU - Haggarty, Stephen J.

PY - 2019/8/21

Y1 - 2019/8/21

N2 - Histone deacetylases (HDACs) are enzymes involved in the epigenetic control of gene expression. A handful of HDAC inhibitors have been approved for the treatment of cancer, and HDAC inhibition has also been proposed as a novel therapeutic strategy for neurodegenerative disorders. These disorders include progranulin (PGRN)-deficient forms of frontotemporal dementia caused by mutations in the GRN gene that lead to haploinsufficiency. Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect. These observations indicate that the kinetics of HDAC inhibitor binding can be tuned for optimal induction of human PGRN expression in neurons. Here, we further expand on these findings using human cortical-like, glutamatergic neurons. We provide evidence that two prototypical, potent hydroxamic acid HDAC inhibitors that induce PGRN (panobinostat and trichostatin A) exhibit an initial fast-binding step followed by a second, slower step, referred to as mechanism B of slow binding, rather than simpler fast-on/fast-off binding kinetics. In addition, we show that trapoxin A, a macrocyclic, epoxyketone-containing class I HDAC inhibitor, exhibits slow binding with high, picomolar potency and also induces PGRN expression in human neurons. Finally, we demonstrate induction of PGRN expression by fast-on/fast-off, highly potent, macrocyclic HDAC inhibitors with ethyl ketone or ethyl ester Zn2+ binding groups. Taken together, these data expand our understanding of HDAC1-3 inhibitor binding kinetics, and further delineate the specific combinations of structural and kinetic features of HDAC inhibitors that are optimal for upregulating PGRN expression in human neurons and thus may have translational relevance in neurodegenerative disease.

AB - Histone deacetylases (HDACs) are enzymes involved in the epigenetic control of gene expression. A handful of HDAC inhibitors have been approved for the treatment of cancer, and HDAC inhibition has also been proposed as a novel therapeutic strategy for neurodegenerative disorders. These disorders include progranulin (PGRN)-deficient forms of frontotemporal dementia caused by mutations in the GRN gene that lead to haploinsufficiency. Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect. These observations indicate that the kinetics of HDAC inhibitor binding can be tuned for optimal induction of human PGRN expression in neurons. Here, we further expand on these findings using human cortical-like, glutamatergic neurons. We provide evidence that two prototypical, potent hydroxamic acid HDAC inhibitors that induce PGRN (panobinostat and trichostatin A) exhibit an initial fast-binding step followed by a second, slower step, referred to as mechanism B of slow binding, rather than simpler fast-on/fast-off binding kinetics. In addition, we show that trapoxin A, a macrocyclic, epoxyketone-containing class I HDAC inhibitor, exhibits slow binding with high, picomolar potency and also induces PGRN expression in human neurons. Finally, we demonstrate induction of PGRN expression by fast-on/fast-off, highly potent, macrocyclic HDAC inhibitors with ethyl ketone or ethyl ester Zn2+ binding groups. Taken together, these data expand our understanding of HDAC1-3 inhibitor binding kinetics, and further delineate the specific combinations of structural and kinetic features of HDAC inhibitors that are optimal for upregulating PGRN expression in human neurons and thus may have translational relevance in neurodegenerative disease.

KW - Epigenetic

KW - histone deacetylase

KW - kinetic profiling

KW - panobinostat

KW - progranulin

KW - slow-binding inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85070935224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070935224&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.9b00281

DO - 10.1021/acschemneuro.9b00281

M3 - Article

VL - 10

SP - 3769

EP - 3777

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 8

ER -